Postoperative Pneumonia After Minimally Invasive Esophagectomy in Esophageal Squamous Cell Carcinoma: A Weighted Real-World Comparison of Neoadjuvant Treatment Strategies.
Neoadjuvant chemoimmunotherapy linked to higher odds of postoperative pneumonia after esophagectomy
Postoperative Pneumonia After Minimally Invasive Esophagectomy in Esophageal Squamous Cell Carcinoma: A Weighted Real-World Comparison of Neoadjuvant Treatment Strategies.
Postoperative pneumonia (postoperative pneumonia) is a critical complication after minimally invasive esophagectomy (minimally invasive esophagectomy) for esophageal squamous cell carcinoma (esophageal squamous cell carcinoma).
This study aimed to compare the associations between different treatment strategies and postoperative pneumonia in this population.
Were divided into four groups: the surgery alone (S-alone) group ( n = 282), the neoadjuvant chemotherapy (neoadjuvant chemotherapy) group ( n = 127), the neoadjuvant chemoradiotherapy (neoadjuvant chemoradiotherapy) group ( n = 60), and the neoadjuvant chemoimmunotherapy (neoadjuvant chemoimmunotherapy) group ( n = 71).
neoadjuvant chemoimmunotherapy nearly doubled the odds of postoperative pneumonia vs surgery alone
In pairwise analyses, the weighted ORs were 0.45 (95% CI , 0.20-1.01) for neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy and 2.32 (95% CI , 1.14-4.71) for neoadjuvant chemoimmunotherapy versus neoadjuvant chemotherapy.
Sensitivity analyses were directionally consistent.
In this single-center observational cohort, neoadjuvant chemoradiotherapy was not associated with higher odds of postoperative pneumonia than S-alone or neoadjuvant chemotherapy, whereas neoadjuvant chemoimmunotherapy was associated with higher odds of postoperative pneumonia.
These findings support careful perioperative respiratory management in patients receiving neoadjuvant immunotherapy.